Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis

Stevenson, M.
Lloyd Jones, M.
De Nigris, E.
Brewer, N.
Davis, S.
Oakley, J.

June 2005

Objectives: To establish the clinical effectiveness and cost-effectiveness of selective oestrogen re...

The Prevention of Postmenopausal Osteoporotic Fractures: Results of the Health Technology Assessment of a New Antiosteoporotic Drug

Chiara de Waure
Maria Lucia Specchia
Chiara Cadeddu
Silvio Capizzi
Stefano Capri
Maria Luisa Di Pietro
Maria Assunta Veneziano
Maria Rosaria Gualano
Flavia Kheiraoui
Giuseppe La Torre
Nicola Nicolotti
Antonella Sferrazza
Walter Ricciardi

January 2014

Objective. The Health Technology Assessment (HTA) approach was applied to denosumab in the preventio...

The prevention of postmenopausal osteoporotic fractures: results of the health technology assessment of a new antiosteoporotic drug

De Waure, Chiara (ORCID:0000-0002-4346-1494)
Specchia, Maria Lucia (ORCID:0000-0002-3859-4591)
Cadeddu, Chiara (ORCID:0000-0003-0149-1078)
Capizzi, Silvio
Di Pietro, Maria Luisa (ORCID:0000-0002-3893-8788)
Veneziano, Maria Assunta
La Torre, Giuseppe
Nicolotti, Nicola
Sferrazza, Antonella
Ricciardi, Gualtiero (ORCID:0000-0002-5655-688X)

January 2014

Objective. The Health Technology Assessment (HTA) approach was applied to denosumab in the preventio...

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

Darbà, Josep
Kaskens, Lisette
Sorio Vilela, Francesc
Lothgren, Mickael

The objective of this study was to estimate the cost-effectiveness of denosumab for fracture prevent...

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

Jönsson, Bengt
Ström, O.
Eisman, John A.
Papaioannou, A.
Siris, E. S.
Tosteson, Anna N. A.
Kanis, John A.

January 2011

Summary: Denosumab is an injectable drug that reduces the risk of fractures. The objective was to es...

Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.

Hiligsmann, Mickaël
Boonen, Annelies
Dirksen, Carmen D.
Ben Sedrine, Wafa
REGINSTER, Jean-Yves

January 2013

Denosumab is a novel biological agent for the treatment of osteoporosis in postmenopausal women with...

Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review

Nargesi, S.
Barghazan, S. H.
Sani'ee, N.
Kemmak, A. R.

January 2022

Background: We aimed to review the systematic economic evaluation of denosumab versus than alternati...

Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women

Hiligsmann, Mickael
Boonen, Annelies
Dirksen, Carmen D.
Ben Sedrine, Wafa
Reginster, Jean-Yves

February 2013

Denosumab is a novel biological agent for the treatment of osteoporosis in postmenopausal women with...

Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.

Hiligsmann, Mickaël
Reginster, Jean-Yves

January 2010

peer reviewedDenosumab has recently been shown to be safe and to significantly reduce the risk of ve...

Research Article The Prevention of Postmenopausal Osteoporotic Fractures: Results of the Health Technology Assessment of a New Antiosteoporotic Drug

Chiara De Waure
Maria Lucia Specchia
Chiara Cadeddu
Silvio Capizzi
Stefano Capri
Maria Luisa
Di Pietro
Maria Assunta Veneziano
Maria Rosaria Gualano
Flavia Kheiraoui
Nicola Nicolotti
Antonella Sferrazza
Walter Ricciardi

August 2016

Cost-Effectiveness of Pharmacological Treatments for Osteoporosis Consistent with the Revised Economic Evaluation Guidelines for Canada.

Coyle, D

January 2018

Introduction. Given the lack of independent analyses comparing numerous pharmacotherapies for osteop...

Denosumab for the prevention of osteoporotic fractures in post-menopausal women

Scotland, Graham
Waugh, Norman
Royle, Pamela
McNamee, Paul
Henderson, Rob
Hollick, Rosemary

November 2011

The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of denosum...

Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis

Ström, O.
Jönsson, Bengt
Kanis, John A.

January 2013

Summary: The objective was to undertake a health economic analysis of denosumab for the treatment of...

Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Waugh, Norman
Royle, Pamela
Scotland, Graham
Henderson, Rob
Hollick, Rosemary
McNamee, Paul

January 2011

This paper presents a summary of the evidence review group (ERG) report into denosumab for the preve...

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden

Söreskog, E.
Lindberg, I.
Kanis, J. A.
Åkesson, K. E.
Willems, D.
Lorentzon, M.
Ström, O.
Berling, P.
Borgström, F.

January 2021

Summary: Romosozumab is a novel bone-building drug that reduces fracture risk. This health economic ...

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis

Stevenson, M.
Lloyd Jones, M.
De Nigris, E.
Brewer, N.
Davis, S.
Oakley, J.

June 2005

Objectives: To establish the clinical effectiveness and cost-effectiveness of selective oestrogen re...

The Prevention of Postmenopausal Osteoporotic Fractures: Results of the Health Technology Assessment of a New Antiosteoporotic Drug

Chiara de Waure
Maria Lucia Specchia
Chiara Cadeddu
Silvio Capizzi
Stefano Capri
Maria Luisa Di Pietro
Maria Assunta Veneziano
Maria Rosaria Gualano
Flavia Kheiraoui
Giuseppe La Torre
Nicola Nicolotti
Antonella Sferrazza
Walter Ricciardi

January 2014

Objective. The Health Technology Assessment (HTA) approach was applied to denosumab in the preventio...

The prevention of postmenopausal osteoporotic fractures: results of the health technology assessment of a new antiosteoporotic drug

De Waure, Chiara (ORCID:0000-0002-4346-1494)
Specchia, Maria Lucia (ORCID:0000-0002-3859-4591)
Cadeddu, Chiara (ORCID:0000-0003-0149-1078)
Capizzi, Silvio
Di Pietro, Maria Luisa (ORCID:0000-0002-3893-8788)
Veneziano, Maria Assunta
La Torre, Giuseppe
Nicolotti, Nicola
Sferrazza, Antonella
Ricciardi, Gualtiero (ORCID:0000-0002-5655-688X)

January 2014

Objective. The Health Technology Assessment (HTA) approach was applied to denosumab in the preventio...

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

Darbà, Josep
Kaskens, Lisette
Sorio Vilela, Francesc
Lothgren, Mickael

The objective of this study was to estimate the cost-effectiveness of denosumab for fracture prevent...

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

Jönsson, Bengt
Ström, O.
Eisman, John A.
Papaioannou, A.
Siris, E. S.
Tosteson, Anna N. A.
Kanis, John A.

January 2011

Summary: Denosumab is an injectable drug that reduces the risk of fractures. The objective was to es...

Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.

Hiligsmann, Mickaël
Boonen, Annelies
Dirksen, Carmen D.
Ben Sedrine, Wafa
REGINSTER, Jean-Yves

January 2013

Denosumab is a novel biological agent for the treatment of osteoporosis in postmenopausal women with...

Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review

Nargesi, S.
Barghazan, S. H.
Sani'ee, N.
Kemmak, A. R.

January 2022

Background: We aimed to review the systematic economic evaluation of denosumab versus than alternati...

Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women

Hiligsmann, Mickael
Boonen, Annelies
Dirksen, Carmen D.
Ben Sedrine, Wafa
Reginster, Jean-Yves

February 2013

Denosumab is a novel biological agent for the treatment of osteoporosis in postmenopausal women with...

Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.

Hiligsmann, Mickaël
Reginster, Jean-Yves

January 2010

peer reviewedDenosumab has recently been shown to be safe and to significantly reduce the risk of ve...

Research Article The Prevention of Postmenopausal Osteoporotic Fractures: Results of the Health Technology Assessment of a New Antiosteoporotic Drug

Chiara De Waure
Maria Lucia Specchia
Chiara Cadeddu
Silvio Capizzi
Stefano Capri
Maria Luisa
Di Pietro
Maria Assunta Veneziano
Maria Rosaria Gualano
Flavia Kheiraoui
Nicola Nicolotti
Antonella Sferrazza
Walter Ricciardi

August 2016

Cost-Effectiveness of Pharmacological Treatments for Osteoporosis Consistent with the Revised Economic Evaluation Guidelines for Canada.

Coyle, D

January 2018

Introduction. Given the lack of independent analyses comparing numerous pharmacotherapies for osteop...

Denosumab for the prevention of osteoporotic fractures in post-menopausal women

Scotland, Graham
Waugh, Norman
Royle, Pamela
McNamee, Paul
Henderson, Rob
Hollick, Rosemary

November 2011

The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of denosum...

Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis

Ström, O.
Jönsson, Bengt
Kanis, John A.

January 2013

Summary: The objective was to undertake a health economic analysis of denosumab for the treatment of...

Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Waugh, Norman
Royle, Pamela
Scotland, Graham
Henderson, Rob
Hollick, Rosemary
McNamee, Paul

January 2011

This paper presents a summary of the evidence review group (ERG) report into denosumab for the preve...

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden

Söreskog, E.
Lindberg, I.
Kanis, J. A.
Åkesson, K. E.
Willems, D.
Lorentzon, M.
Ström, O.
Berling, P.
Borgström, F.

January 2021

Summary: Romosozumab is a novel bone-building drug that reduces fracture risk. This health economic ...

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis

Stevenson, M.
Lloyd Jones, M.
De Nigris, E.
Brewer, N.
Davis, S.
Oakley, J.

June 2005

Objectives: To establish the clinical effectiveness and cost-effectiveness of selective oestrogen re...

The Prevention of Postmenopausal Osteoporotic Fractures: Results of the Health Technology Assessment of a New Antiosteoporotic Drug

Chiara de Waure
Maria Lucia Specchia
Chiara Cadeddu
Silvio Capizzi
Stefano Capri
Maria Luisa Di Pietro
Maria Assunta Veneziano
Maria Rosaria Gualano
Flavia Kheiraoui
Giuseppe La Torre
Nicola Nicolotti
Antonella Sferrazza
Walter Ricciardi

January 2014

Objective. The Health Technology Assessment (HTA) approach was applied to denosumab in the preventio...

The prevention of postmenopausal osteoporotic fractures: results of the health technology assessment of a new antiosteoporotic drug

De Waure, Chiara (ORCID:0000-0002-4346-1494)
Specchia, Maria Lucia (ORCID:0000-0002-3859-4591)
Cadeddu, Chiara (ORCID:0000-0003-0149-1078)
Capizzi, Silvio
Di Pietro, Maria Luisa (ORCID:0000-0002-3893-8788)
Veneziano, Maria Assunta
La Torre, Giuseppe
Nicolotti, Nicola
Sferrazza, Antonella
Ricciardi, Gualtiero (ORCID:0000-0002-5655-688X)

January 2014

Objective. The Health Technology Assessment (HTA) approach was applied to denosumab in the preventio...

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

Abstract

Extracted data

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

Abstract

Extracted data

Related items

Related items